Breast cancer research : BCR · 2026
H-score and ERBB2 mRNA refine identification of HER2-low and HER2-ultralow breast cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sartori Guilherme Parisotto, Ramalho Susana, da Silva Leonardo Roberto, Telles Guilherme Defante, Zaffaroni Facundo, de Paiva Geisilene Russano, da Rosa Mahira Lopes, Reinert Tomás, Coelho Guilherme, Mandelli Jovana, Tavares Grazielle Morais, Mantovani Higor Kassouf, Vasconcelos Vivian, da Silva Cabello Ana Elisa Ribeiro, Cabello César, Barrios Carlos, Graudenz Marcia Silveira
Аннотация
BACKGROUND: Accurate HER2 assessment is essential for breast cancer (BC) treatment, as it directs targeted therapy decisions and predicts patient prognosis. Even though immunohistochemistry (IHC) is widely used, manual scoring is susceptible to variability. This study was conducted to evaluate HER2 expression in HER2-negative breast cancer patients treated with neoadjuvant chemotherapy (NAC), using H-score and ERBB2 mRNA quantification.
METHODS: We conducted a retrospective cohort study in breast cancer patients treated with NAC between 2017 and 2023. H-score was evaluated in 506 patients. For gene expression analyses, only tumors with available H-score and Ct ≤ 35 for all candidate reference genes were included, resulting in 173 evaluable cases for ERBB2 mRNA quantification. HER2-zero tumors were further stratified into HER2-null (H-score = 0) and HER2-ultralow (H-score 1-120) groups.
RESULTS: Among all 506 HER2-negative tumors, 54.6% were classified as HER2-low and 45.4% as HER2-zero. Within the HER2-zero subgroup, 47.4% showed measurable HER2 expression (HER2-ultralow). ERBB2 mRNA levels were significantly higher in HER2-low tumors compared to HER2-zero. Among HER2-zero, HER2-ultralow tumors had higher ERBB2 expression than HER2-null. Higher H-scores were associated with increased ERBB2 transcript expression, according to Spearman correlation coefficient (p < 0.05). HER2-null tumors were more frequently triple-negative.
CONCLUSIONS: Quantitative assessment by H-score and ERBB2 transcript analysis reveals heterogeneity within HER2-zero tumors, identifying a HER2-ultralow population with potentially distinct clinical behavior. These findings support the integration of continuous HER2 expression metrics into clinical decision-making and trial design, particularly in the era of HER2-targeted antibody-drug conjugates.
METHODS: We conducted a retrospective cohort study in breast cancer patients treated with NAC between 2017 and 2023. H-score was evaluated in 506 patients. For gene expression analyses, only tumors with available H-score and Ct ≤ 35 for all candidate reference genes were included, resulting in 173 evaluable cases for ERBB2 mRNA quantification. HER2-zero tumors were further stratified into HER2-null (H-score = 0) and HER2-ultralow (H-score 1-120) groups.
RESULTS: Among all 506 HER2-negative tumors, 54.6% were classified as HER2-low and 45.4% as HER2-zero. Within the HER2-zero subgroup, 47.4% showed measurable HER2 expression (HER2-ultralow). ERBB2 mRNA levels were significantly higher in HER2-low tumors compared to HER2-zero. Among HER2-zero, HER2-ultralow tumors had higher ERBB2 expression than HER2-null. Higher H-scores were associated with increased ERBB2 transcript expression, according to Spearman correlation coefficient (p < 0.05). HER2-null tumors were more frequently triple-negative.
CONCLUSIONS: Quantitative assessment by H-score and ERBB2 transcript analysis reveals heterogeneity within HER2-zero tumors, identifying a HER2-ultralow population with potentially distinct clinical behavior. These findings support the integration of continuous HER2 expression metrics into clinical decision-making and trial design, particularly in the era of HER2-targeted antibody-drug conjugates.